Artículos de revistas
Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis
Registro en:
Plos One. Public Library Science, v. 7, n. 8, 2012.
1932-6203
WOS:000307823600045
10.1371/journal.pone.0043090
Autor
Traina, F
Visconte, V
Jankowska, AM
Makishima, H
O'Keefe, CL
Elson, P
Han, YC
Hsieh, FH
Sekeres, MA
Mali, RS
Kalaycio, M
Lichtin, AE
Advani, AS
Duong, HK
Copelan, E
Kapur, R
Saad, STO
Maciejewski, JP
Tiu, RV
Institución
Resumen
We hypothesized that analysis of single nucleotide polymorphism arrays (SNP-A) and new molecular defects may provide new insight in the pathogenesis of systemic mastocytosis (SM). SNP-A karyotyping was applied to identify recurrent areas of loss of heterozygosity and bidirectional sequencing was performed to evaluate the mutational status of TET2, DNMT3A, ASXL1, EZH2, IDH1/IDH2 and the CBL gene family. Overall survival (OS) was analyzed using the Kaplan-Meier method. We studied a total of 26 patients with SM. In 67% of SM patients, SNP-A karyotyping showed new chromosomal abnormalities including uniparental disomy of 4q and 2p spanning TET2/KIT and DNMT3A. Mutations in TET2, DNMT3A, ASXL1 and CBL were found in 23%, 12%, 12%, and 4% of SM patients, respectively. No mutations were observed in EZH2 and IDH1/IDH2. Significant differences in OS were observed for SM mutated patients grouped based on the presence of combined TET2/DNMT3A/ASXL1 mutations independent of KIT (P = 0.04) and sole TET2 mutations (P<0.001). In conclusion, TET2, DNMT3A and ASXL1 mutations are also present in mastocytosis and these mutations may affect prognosis, as demonstrated by worse OS in mutated patients. 7 8 Celgene Future Leaders of Hematology Award Howard Hughes Medical Institute